Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview;Schizofrenie en antipsychotica: Samenhang met het metabool syndroom

Tijdschrift voor Psychiatrie

Volumn 50, Issue 10, 2008, Pages 645-654

  Scheepers Hoeks, A M J W ^a   Wessels Basten, S J W ^a   Scherders, M J W T ^a   Bravenboer, B ^a   Loonen, A J M ^b   Kleppe, R T ^c   Grouls, R J E ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Kempen te Eindhoven

Author keywords

Antipsychotics; Cardiovascular risk; Diabetes mellitus type 2; Metabolic syndrome; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

ABDOMINAL OBESITY; ARTICLE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HUMAN; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SCHIZOPHRENIA;

ABDOMINAL FAT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; METABOLIC SYNDROME X; RISK FACTORS; SCHIZOPHRENIA;

EID: 54349120262     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Alberti, K.G., Zimmet, P., & Shaw, J. (2005). The metabolic syndrome - a new worldwide definition. Lancet, 366, 1059-1062.
2. American Diabetes Association, American Psychiatry Association, American Association of Clinical Endocrinologists, e.a. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. The Journal of Clinical Psychiatry, 65, 267-272.
3. Bellivier, F. (2005). Schizophrenia, antipsychotics and diabetes: genetic aspects. European Psychiatry, 20, S335-S339.
4. Bijl, A.M.H. (2006). Diabetes door atypische antipsychotica. Pharmaceutisch Weekblad, 141, 164-165.
5. Bottai, T., Quintin, P., & Perrin, E. (2005). Antipsychotics and the risk of diabetes: a general data review. European Psychiatry, 20 (suppl. 4), S349-S357.
6. Buse, J.B., Cavazzoni, P., Hornbuckle, K., e.a. (2003). A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 56, 164-170.
7. Cahn, W., Ramlal, D., Bruggeman, R., e.a. (2008). Preventie en behandeling van somatische complicaties bij antipsychoticagebtuik. Tijdschrift voor Psychiatrie, 50, 579-591.
8. Casey, D.E. (2004). Dyslipidemia and atypical antipsychotic drugs. The Journal of Clinical Psychiatry, 65(suppl. 18), 27-35.
9. Casey, D.E. (2005). Metabolic issues and cardiovascular disease in patients with psychiatric disorders. The American Journal of Medicine, 118 (suppl. 2), S15-S22.
10. Citrome, L. (2005). Metabolic syndrome and cardiovascular disease. Journal of Psychopharmacology (Oxford, England), 19 (6 Suppl.), S84-S93.
11. Citrome, L., Jaffe, A., Levine, J., e.a. (2004). Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Services (Washington, DC), 55, 1006-1013.
12. Cohen, D., Dekker, J. J., Peen, J., e.a. (2006a). Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. European Neuropsychopharmacology, 16, 187-194.
13. Cohen, D., Stolk, R.P., Grobbee, D.E., e.a. (2006b). Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care, 29, 786-791.
14. Colin, T., Prud'homme, D., Streiner, D., e.a. (2004). Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry, 49, 753-760.
15. Correll, C.U., Frederickson, A.M., Kane, J.M., e.a. (2006). Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. The Journal of Clinical Psychiatry, 67, 575-583.
16. Eckel, R.H., Grundy, S.M., & Zimmet, P.Z. (2005). The metabolic syndrome. Lancet, 365, 1415-1428.
17. Feldman, P.D., Hay, L.K., Deberdt, W., e.a. (2004). Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. Journal of the American Medical Directors Association, 5, 38-46.
18. Fenton, W.S., & Chavez, M.R. (2006). Medication-induced weight gain and dyslipidemia in patients with schizophrenia. The American Journal of Psychiatry, 163, 1697-1704.
19. Gaal, L.F. van (2006). Long-term health considerations in schizophrenia: metabolic effects and the tole of abdominal adiposity. European Neuropsychopharmacology, 16(Suppl. 3), S142-S148.
20. Gianfrancesco, F.D., Grogg, A.L., Mahmoud, R.A., e.a. (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Journal of Clinical Psychiatry, 63, 920-930.
21. Gianfrancesco, F.D., Grogg, A., Mahmoud, R., e.a. (2003). Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clinical Therapeutics, 25, 1150-1171.
22. Guo, J.J., Keck, P.E., Corey-Lisle, P.K., e.a. (2006). Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry, 67, 1055-1061.
23. Hägg, S., Lindblom, Y., Mjörndal, T., e.a. (2006). High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology, 21, 93-98.
24. Heiskanen, T., Niskanen, L., Lyytikäinen, R., e.a. (2003). Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 64, 575-579.
25. Hert, M. de, van Winkel, R., van Eyck, D., e.a. (2006). Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health, 2, 14.
26. Hert, M. de, Schreurs, V., Sweers, K., e.a. (2008). Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research, 101, 295-303.
27. Huang, T.L., & Chen, J.F. (2005). Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophrenia Research, 80, 55-59.
28. International Diabetes Foundation. (2005). IDF-consensus worldwide definition of the metabolic syndrome. Brussel: IDF. http://www.idf.org/webdata/ docs/Metabolic-syndrome-definition.pdf
29. Isomaa, B., Almgren, P., Tuomi, T., e.a. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683-689.
30. Kornegay, C.J., Vasilakis-Scaramozza, C., & Jick, H. (2002). Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Journal of Clinical Psychiatry, 63, 758-762.
31. Lambert, T.J., & Chapman, L.H. (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. The Medical Journal of Australia, 181, 544-548.
32. Lamberti, J.S., Olson, D., Crilly, J., e.a. (2006). Prevalence of the metabolic syndrome among patients receiving clozapine. The American Journal of Psychiatry, 163, 1273-1276.
33. Lieberman, J.A. 3rd. (2004). Metabolic changes associated with anti-psychotic use. Primary Care Companion to The Journal of Clinical Psychiatry, 6(Suppl. 2), S8-S13.
34. Lindenmayer, J.P., Czobor, P., Volavka, J., e.a. (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry, 160, 290-296.
35. McEvoy, J.P., Meyer, J.M., Goff, D.C., e.a. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32.
36. Meigs, J.B. (2005). The metabolic syndrome (insulin resistance syndrome or syndrome X). UpToDate, 11-5-2006.
37. http://www.uptodate.com/patients/content/topic.do?topicKey= 1Z1VHULNGNovPhK&selectedTitle=1147&source=search-result
38. Melkersson, K.I., Dahl, M.L., & Hulting, A.L. (2004). Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl.), 175, 1-6.
39. Meyer, J.M. (2005). Schizophrenia and the metabolic syndrome. Medscape Psychiatry & Mental Health, 10. http://www.medscape.com.
40. Meyer, J.M., Nasrallah, H.A., McEvoy, J.P., e.a. (2005a). The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research, 80, 9-18.
41. Meyer, J.M., Pandina, G., Bossie, C.A., e.a. (2005b). Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clinical Therapeutics, 27, 1930-1941.
42. Muller, D.J., Muglia, P., Fortune, T., e.a. (2004). Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research, 49, 309-329.
43. Newcomer, J.W. (2004). Metabolic risk during antipsychotic treatment. Clinical Therapeutics, 26, 1936-1946.
44. Newcomer, J.W. (2006). Medical risk in patients with bipolar disorder and schizophrenia. The Journal of Clinical Psychiatry, 67 (Suppl. 9), S25-S30.
45. Olijhoek, J.K., Martens, F.M.A.C., Banga, J.D., e.a. (2005). Het metabool syndroom: een cluster van vasculaire risicofactoren. Nederlands Tydschrift voor Geneeskunde, 149, 859-865.
46. Ollendorf, D.A., Joyce, A.T., & Rucker, M. (2004). Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed: Medscape General Medicine, 6, 5.
47. Osby, U., Correia, N., Brandt, L., e.a. (2000). Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ, 321, 483-484.
48. Sernyak, M.J., Leslie, D.L., Alarcon, R.D., e.a. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. The American Journal of Psychiatry, 159, 561-566.
49. Wijk, J.P.H. van, & Rabelink, T.J. (2003). Het metabool syndroom gedijt bij inactiviteit. Pharmaceutisch Weekblad, 138, 1564-1567.